European Association of Urology

🎧 In this new episode of #EAUPodcasts on "How to handle adverse events after instillation therapy," Prof. Alexandra Masson-Lecomte (FR) and Prof. Fred Witjes (NL) discuss a case that highlights the challenges healthcare providers face when managing post-treatment complications. They explore adverse reactions, underlying causes, and strategies to mitigate the effects of instillation therapy while ensuring optimal patient outcomes. Whether you are a seasoned clinician or a healthcare professional looking to expand your knowledge, this episode offers valuable insights into the complexities of instillation therapy management. Tune in as we examine how to enhance patient safety and improve therapeutic efficacy through informed decision-making and practical solutions. 👉https://lnkd.in/e3NExUFR

Vacature! Ben jij die ervaren systeembeheerder die IT-problemen van eindgebruikers weet op te lossen? Ben je niet bang voor een complexe uitdaging en gebrand op het voorkomen van problemen? Dan zijn we op zoek naar jou! #vacature #arnhem https://lnkd.in/ejab-njW

You’re still eligible for the 40% discount when you register for #EMUC24! Collect CME credits as well (EMUC24 is accredited with a max of 22.5 CME credits). Join us in Lisbon and enjoy an interdisciplinary programme: ✅13 Plenary Sessions ✅EAU Section of Urological Imaging meeting ✅Special guest lecture ✅ESUP Symposium on Genitourinary Pathology and Molecular Diagnostics ✅FALCON workshop ✅European School of Urology courses and Hands-on Training, to name a few! Sign up with the reduced rates here 👉 https://lnkd.in/gxZ69Gz

️Would you like to showcase your important research to a worldwide audience of urology experts? You can now submit your abstract for the 40th Annual EAU Congress (#EAU25), to be held in Madrid from 21-24 March, 2025. 🏆 Prizes will be given to the most outstanding abstracts in the following categories: Oncology, Non-Oncology, Best Abstract by a Resident, and Best Video. Don't miss the opportunity to share your original work and play a key role in enhancing patient care. ⏰Abstract submission deadline: 1 November 2024 (23:59 CET). See more details here 👇 https://lnkd.in/gEMbdB5

📹 In this exclusive interview from UROonco24, Dr. Juan Gómez Rivas and Dr. Ursula Vogl discuss advancements in genomic profiling and the use of PARP inhibitors in treating metastatic prostate cancer, with a focus on genomic profiling, patient selection and toxicity management. Dr. Vogl highlights the importance of testing both somatic and germline mutations to ensure patients receive the best treatment. She shares her expert opinion on PARP inhibitors and how to manage toxicities with careful monitoring and adjustments, stressing the need for personalised treatment approaches. 👇 #prostatecancer #oncology

This year, the #EMUC24 Congress will feature two plenary sessions designed by the Kidney Cancer Association (KCA). This new collaboration enables the dissemination of their RCC updates within a multidisciplinary environment. Dr. Salvatore La Rosa (US), Chief Scientific Officer of the KCA is enthusiastic about their contribution to the EMUC24 programme: “As a non-profit advocacy organisation, we are thrilled to collaborate with EMUC this year to deliver cutting-edge research summaries and valuable RCC education to attendees. Our aim is to empower clinicians with the knowledge and tools they need to provide the highest quality care for their patients.” “In today’s digital age, patients and their families have access to vast amounts of information online about their diagnoses. However, it’s crucial that they receive accessible, evidence-based, and up-to-date information about RCC to make informed decisions and advocate for their options. We hope to reach more health professionals with information that can be passed on to their patients, ultimately helping them to navigate their cancer journey with confidence.” “For KCA, whose mission is to find a cure for kidney cancer, this collaboration is a unique opportunity to bring together experts from various specialties to address the latest topics and challenges in renal cancer. This is particularly significant with urologists, who are often not as involved in RCC patient care as they should. By leveraging the EMUC platform, we also aim to draw more attention from other specialists to RCC and attract them to the field by presenting them with the unique challenges our patients face at every step of their journey.” ◾ What’s on the agenda? The first KCA plenary session will take place on Friday 8 November from 16:15 till 17:30 and will feature presentations on several key practice-changing studies, including trial results from FASTRACK, KEYNOTE 564 OS, and SUNNiFORCAST. There will also be a debate on evidence for local tumour control in metastatic RCC. ◾Experience a WoodFire® session The second KCA Plenary Session will take place on Saturday 9 November from 11:40 till 12:45 and will introduce a unique format to the EMUC24 programme called a WoodFire® session. Dr. La Rosa explains: “This is essentially a live tumour board. It got its name due to the quick-fire, high-pressure nature of how our late Board of Directors Chair, Dr. Christopher G. Wood, a renowned surgeon at MD Anderson Cancer Center in Houston, Texas, grilled his peers about how they might treat someone with RCC – all in good fun! It is fascinating to hear how differently a surgeon might approach a single case versus a medical oncologist versus a urologist, and so on. WoodFire® is both a glimpse at how much we must learn from each other and a testament to how much everyone cares about achieving a good outcome for the patient.” — EMUC24 will take place in Lisbon, Portugal from 7-10 Nov 2024. More info 👉 https://ow.ly/8KSF50TcZBW

Craft the perfect abstract, report accurate stats, and deliver impactful presentations through this new UROwebinar. Get the must-have skills in presenting your research in the most effective and efficient way possible, sign up now! Registration link in the comments section 👇

The therapeutic value of lymph node dissection (LND) for patients with muscle-invasive bladder cancer (MIBC) is a topic of continuous debate. The two prospective randomised trials investigating the anatomic extend of the LND are the German LEA trial and the US/Canadien SWOG S1011 trial. In the LEA trial, patients with MIBC (n = 346) or T1G3 disease (n = 55) were included. Patients underwent either a limited LND (n= 203) or extended LND (n = 198). Survival differences between the groups were seen, in favour of extended LND. However, extended LND failed to show a significant advantage (the trial was designed to show an absolute improvement of 15% in 5-year RFS by extended LND) over limited LND for RFS, CSS, and OS. The results of the SWOG S1011 trial comparing standard versus extended LND, presented at the 2023 ASCO meeting, showed in patients with clinically localised bladder cancer after a median six years follow-up no DFS (HR 1.10 [95%CI 0.87-1.42] p=0.4) or OS (HR 1.15 [95%CI 0.89-1,48] p=0.29) benefit for an extended LND. It does, however, increase the risk of side effects and post-operative mortality. In conclusion, based on these two RCT’s, an extended LND, is not associated with improved survival and increases the risk of morbidity. #MIBC #eauguidelines Recommendations are posted daily on 'X' and weekly on LinkedIn. For more recommendations visit our website: https://lnkd.in/eRS6XpvY

📹 At the UROonco24 meeting in Budapest, Dr. Gianluca Giannarini interviewed medical oncologist Dr. Elena Castro on the challenges of managing treatment-related toxicity and quality of life for PCa patients. Dr. Castro discusses treatment intensification, oncological outcomes, and side effects, particularly in hormone-sensitive patients. Dr. Castro suggests that intermittent or selective treatment could help reduce these toxicities. She also reviews the common side effects of androgen receptor inhibitors, chemotherapy, PARP inhibitors and other therapies, emphasising the importance of multidisciplinary collaboration to manage these toxicities effectively and maintain patient quality of life. 👇 #prostatecancer #oncology

What is the optimal way to overcome resistance development for prostate biopsy? Do you opt for the TP or TRUS approach? Find out during this new #UROwebinar tomorrow! Link to registration + CME credit in the comments section 👇